Abstract
Despite the emergence of JAK inhibitors, there is a need for disease-modifying treatments for Philadelphia-negative myeloproliferative neoplasms (MPNs). JAK inhibitors ameliorate symptoms and address splenomegaly, but because of the heterogeneous contributors to the disease process, JAK inhibitor monotherapy incompletely addresses the burden of disease. The ever-growing understanding of MPN pathogenesis has provided the rationale for testing novel and targeted therapeutic agents, as monotherapies or in combination, in preclinical and clinical settings. A number of intriguing options have emerged, and it is hoped that further progress will lead to significant changes in the natural history of MPNs.
Original language | English (US) |
---|---|
Pages (from-to) | 17-25 |
Number of pages | 9 |
Journal | EBioMedicine |
Volume | 3 |
DOIs | |
State | Published - Jan 1 2016 |
Keywords
- Combination
- Myelofibrosis
- Myeloproliferative neoplasm
- Novel
- Targeted
- Therapy
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology